NCT04857606 - Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

July 19, 2023

Study Completion Date

July 19, 2023

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG

AMG 609

Single dose of AMG 609 administered as a subcutaneous injection.

DRUG

Placebo

Single dose of placebo administered as a subcutaneous injection.

Trial Locations (10)

McGuire VA Medical Center, Richmond

Translational Clinical Research LLC, Aventura

Texas Liver Institute, San Antonio

Endeavor Clinical Trials, San Antonio

Pinnacle Clinical Research, San Antonio

The Institute for Liver Health - Arizona Liver Health, Chandler

Catalina Research Institute, Montclair

ProSciento Incorporated, Chula Vista

Inland Empire Liver Foundation, Rialto

Orange County Research Center, Tustin